Targazyme, Inc.

Targazyme, Inc. is a clinical-stage biopharmaceutical company developing and commercializing breakthrough products to improve clinical efficacy outcomes for immunotherapies for cancer and autoimmune diseases, stem cell transplants, gene therapy and regenerative medicine.

Targazyme is driving towards a product registration trial in hematopoietic stem cell transplantation and proof of concept clinical trials in immunotherapy.  The company’s platform technologies improve the therapeutic potential of cells by directing therapeutic cells to sites of inflammation, ischemia and/or tissue damage in the body and improving retention in those tissues.  By directing these cells to where they are most needed, Targazyme’s technologies can improve the effectiveness of therapeutic cells in numerous disease indications.